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Introduction
Mast cells (MC) are ubiquitously expressed in almost all tissue and 
participate as effector cells for immune regulation. Peripheral blood 
basophils (PBB) are similar to MC in that they have pre-stored, allergy-
inducing mediators in their granules (e.g. histamine). Once stimulated, 
MC/PBB secretes several molecules, including preformed and newly 
formed inflammatory mediators, via various physiological and non-
physiological stimulations [1-3]. While the classical IgE/FcεRI pathway 
is the most well studied and understood pathway leading to MC/PBB 
mediator release, these cells can be stimulated by non-IgE secretagogues. 
Indeed, non-IgE stimulation may be more physiologically relevant in 
non-allergic conditions such as innate immunity and heart disease 
[2-4]. Thus, finding new ways to stabilize these cells as a strategy for 
controlling MC/PBB-diseases is a continuous need. 
Fullerenes, which are nanometer-sized tiny spherical carbon 
cages, are being explored in a wide array of applications including 
nanomedicine [5,6]. The carbon cage is insoluble without the addition 
of appropriate side chains that confer water solubility, an important 
requirement for medical applications. Recent studies suggest that 
water-soluble fullerene derivatives (FD) can inhibit FcεRI-induced MC 
responses in vitro, which translates to the prevention of MC-driven 
anaphylaxis and asthma in vivo [7-9]. Although it is clear certain FD 
can stabilize MC activation through FcεRI in vitro and in vivo it is not 
known if they can stabilize MC activation through non-FcεRI-mediated 
stimuli. In these studies, the non-FcεRI/IgE mediated inhibitory effects 
of a panel of FD were tested for their ability to stabilize MC/PBB.
It is shown that incubation of MC/PBB with fullerene constructs 
can significantly inhibit mediator release in response to various 
secretagogues. This inhibition was mediated in part through reductions 
in the generation of reactive oxygen species (ROS), cellular fluctuations 
of calcium, and phosphorylation of signaling molecules in activated 
MC. It is demonstrated that FD inhibit non-IgE mediated pathways and 
the efficacy of FD relies on several factors: the active side chain moieties 
added to the fullerene cage, the type of cells evaluated, the secretagogue 
used to stimulate, and the pathway that is examined.
Materials and Methods:
Reagents
The following reagents: A23187 (calcium ionophore), compound 
48/80 (polymer amine synthesized by condensing methyl-p-methoxy 
phenylethylamine with formaldehyde), somatostatin, poly L-lysine, 
and N-formyl-methionine-leucine-phenylalanine (fMLP), Fura-2/AM, 
4-nitrophenyl 2-acetamido-2-deoxy-β-D-glucopyranoside (PNP) (all 
from Sigma-Aldrich Corp., St. Louis, MO.), purified mouse α-human 
TNF-α (Mouse IgG1, clone MAb1), rat α-Human GM-CSF (Rat IgG2a, 
clone BVD2-23B6), rat α-human IL-13 (Rat IgG1, clone JES10-5A2), 
biotin mouse α-human TNF (Mouse IgG1, clone MAb1), biotin rat 
α-human GM-CSF (Rat IgG2a, clone BVD2-23B6), biotin rat α-human 
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Abstract
Mast cells (MC) and peripheral blood basophils (PBB) are well known for their role in the allergic response 
mediated through high affinity IgE receptors (FcεRI). However, these cells can also be stimulated by other non-allergic 
secretagogues to release their inflammatory mediators. Certain fullerene derivatives (FD) have already been shown 
to stabilize FcεRI-mediated MC/PBB responses, but it is not know if they also stabilize these cells through non-IgE-
mediated mechanisms. A panel of FD was synthesized and tested for their ability to inhibit non-FcεRI mediated release 
from human MC and PBB. It was found that specifically engineered FD could significantly inhibit calcium ionophore, 
compound 48/80, somatostatin, and poly L-lysine induced MC degranulation and cytokine production, as well as blunt 
degranulation and cytokine production from N-formyl-methionine-leucine-phenylalanine (fMLP), poly L-lysine, and 
calcium ionophore stimulated PBB. The mechanism of inhibition was due in part to the prevention of secretagogue-
induced increases in cellular reactive oxygen species (ROS) and calcium levels as well as the reduced activation 
of the MAPK signaling intermediates ERK1/ERK2 and LAT. Additionally, preincubation of MC with FD blunted the 
prostaglandin D2 (PGD2) production upon exposure to inflammatory stimuli. In both cell types, the extent of inhibition of 
mediator release in response to each secretagogue was dependent on the moieties/side chains attached to the carbon 
cage. These results further extend the utility of fullerene nanomaterials to control mediator release through non-IgE 
mediated pathways in MC/PBB.
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IL-13 (Rat IgG1, clone JES10-5A2), avidin-horseradish peroxidase (all 
from BD Biosciences, San Jose, CA), X-Vivo 15 with gentamicin, L-Glu, 
phenol red (Lonza, Walkersville, MD), human stem cell factor (SCF; 
Peprotech, Rocky Hill, NJ), and DCF-DA (Cayman Chemical Company, 
Ann Arbor, MI.) were obtained from the indicated commercial sources 
and used as described.
Fullerene derivatives
Luna Innovations Incorporated synthesized all FD. Each FD was 
characterized using matrix assisted laser desorption ionization mass 
spectrometry (MALDI-TOF), nuclear magnetic resonance (NMR), and 
high performance liquid chromatography (HPLC). All FD used were 
between 1 and 50 nm in aqueous solution as determined by dynamic 
light scattering (DLS) using a Malvern Zetasizer Nano-S90 and a 
NanoSight LM10 with NTA Software allowing individual particles to 
be tracked and characterized. To evaluate fullerene-specific toxicity, 
MC viability was determined by incubation with concentrations up 
to 100 µg/ml over nine days (a 10x higher concentration and longer 
time period than was needed to control cellular responses to stimuli). 
No significant (p<0.05) toxicity was observed with any of the selected 
compounds when compared to controls as determined using trypan 
blue staining and MTT Assay (data not shown).
Human MC and PBB cultures and activation
Human tissue (i.e. skin) was received from the Cooperative Human 
Tissue Network. All MC studies were approved by their Human Studies 
Institutional Review Board. Mast cells were purified and cultured 
as described [10,11]. Peripheral blood basophils were obtained from 
normal donors (no medications) after informed consent as approved by 
the Institutional Review Board, Johns Hopkins University and purified 
to >90% as described previously [12].
A panel of FD was screened at several concentrations to determine 
their ability to inhibit secretion. Briefly, MC/PBB were first incubated 
with increasing concentrations of FD (1-40 µg/ml) overnight (18 hours) 
at 37°C and 6% CO2, a time point and concentration range found to 
be optimal for cellular uptake of FD [8,13]. The next day, cells were 
stimulated with the indicated secretagogues at varied concentrations 
for 30 minutes (degranulation and PGD2) or overnight (cytokine 
production) at 37°C and mediator release measured as described 
previously or according to the manufactures instructions (Cayman 
Chemical Company, Ann Arbor, MI, Prostaglandin D2 Kit-512031). 
The percent inhibition was calculated as a percent release compared 
to non-FD treated cells (positive control). An initial dose response 
was performed to determine the concentration of secretagogues that 
induced maximal degranulation/cytokine production (not shown). In 
short, MC responded optimally to 10 µM with A23187 and compound 
48/80, 20 µM for somatostatin, and 40 µM for poly L-lysine. Other 
secretagogues (C5a, morphine, substance P, and LPS) were examined, 
however preincubation with FD did not produce statistically significant 
reductions in MC mediator release or stimuli did not induce significant 
activation (data not shown). For PBB, 10 µM was optimal activation 
with fMLP, poly L-lysine, and A23187 (data not shown). All studies 
were performed in triplicate on at least three separate MC cultures or 
PBB donors.
Reactive oxygen species and calcium measurements
Human skin MC (2x106/ml) were incubated overnight with FD 
(those found to significantly inhibit degranulation and/or cytokine 
release), washed, and loaded with DCF-DA (final concentration of 5 
μM) for 30 minutes. Following fluorophore loading, cells were washed 
and resuspended in fresh media, placed in a cuvette, and activated with 
various secretagogues (as above) for ~60 seconds. ROS fluorescence 
intensity was measured at 523 nm wavelengths over a 12-minute 
time interval using Perkin Elmer LS55 Luminescent Spectrometer 
(Perkin-Elmer Laboratories). For calcium flux, MC (incubated as 
above) was loaded with Fura-2  AM at a final concentration of 20 
ng/ml for 30 minutes at 37°C in HBSS buffer. The cells were washed 
twice in the same buffer and incubated for 15 minutes. The cells were 
then stimulated with appropriate secretagogues and a real time ratio-
metric intensity evaluation of fluorescence between wavelengths 340 
nm/380 nm was determined over a period of 400 seconds using Perkin 
Elmer LS55 Luminescent Spectrometer. All samples were measured in 
duplicate and performed at least three times. 
Immunoblotting analysis of signal transduction intermediates
Mast cells (1x107 cell/condition; each condition performed in 
triplicate) were prepared for Western blotting as described previously 
[8]. Briefly, cells were incubated with or without optimal concentrations 
of the indicated FD overnight, washed, and activated as described 
above. Cell pellets were lysed and nuclear extracts isolated as described 
[14]. The cell suspension was heated, passed through a 20-gauge needle, 
and centrifuged to remove cell debris. Proteins were separated on 12% 
NuPage tris-glycine gels using tris-glycine SDS running buffer. Signaling 
molecules were measured using phosphorylated MAPK (ERK1 and 
ERK2) and LAT primary antibodies (Santa Cruz Biotechnology, 
Santa Cruz, CA or Cell Signaling, Danvers, MA, respectively) and 
Licor IR-800 anti-mouse F (ab)2 secondary antibodies (1:20,000). The 
housekeeping protein β-actin was used as a loading control on the same 
blot and co-stained with Licor IR-600 anti-rabbit F (ab)2 secondary 
antibodies. Band intensities were quantified using an Odyssey Imaging 
System as previous described [8].
Results
FD differentially effect MC non-IgE-induced mediator release
A panel of water soluble FD was evaluated to determine efficacy 
based on various side chain moieties as well as differential responses 
to numerous secretagogues. Table 1 presents results from a subset 
(~30%) of FD that was capable of significantly (p<0.05) inhibiting MC-
Fullerene 
Derivative A23187 + FD* 48/80 + FD*
somatostatin 
+FD*
poly-L-lysine 
+ FD*
Biotin no Inh no Inh 44.6 (±1.8)¥¥¥ no Inh
C70-OH 19.0 (±1.1)¥¥¥ 42.0 (±4.6)¥¥¥ 13.4 (±5.2)¥ 33.4 (±5.5)¥¥¥
CCC no Inh no Inh 23.8 (±0.8)¥¥¥ no Inh
DMAE 18.6  (±7.9)¥ 16.9 (±10.)¥¥¥ 24.3 (±9.7)¥ no Inh
Ethanolamine 36.0 (±3.0)¥¥¥ no Inh no Inh no Inh
Niacin no Inh 59.5 (±1.3)¥¥¥ 21.9 (±13.8)¥ 20.9 (±12.6)¥
NSAID 21.1 (±11.4)¥ no Inh no Inh no Inh
PC4 no Inh no Inh 21.6 (±2.9)¥¥¥ no Inh
Tetraglutamate 22.3 (±3.9)¥¥¥ no Inh 20.3 (±4.5)¥¥ 17.9 (±13.1)¥
Tetrainositol no Inh no Inh 32.8 (±1.9)¥¥¥ no Inh
Tetraphosphate 18.9 (±0.4)¥¥¥ no Inh no Inh no Inh
Tetrapyridine 14.0 (±1.9)¥¥ 34.8 (±8.1)¥¥ no Inh 13.1 (±4.0)¥
Tetrasulfonate 21.1 (±6.3)¥ 44.8 (±11.2)¥¥ 22.0 (±5.50)¥¥ 26.7 (±2.3)¥¥
TGA  49.8 (±8.9)¥¥¥ no Inh 16.7 (±3.8)¥¥¥ 43.8 (±10.6)¥¥
TTA no Inh no Inh 34.6 (±2.6)¥¥¥ 52.4 (±4.3)¥¥¥
* FD Treatment at 10 µg/mL. ¥¥¥ p value < 0.01 / ¥¥ p value < 0.02 / ¥ p value < 0.05 
/ no Inh = no significant inhibition observed
Table 1: Mean % inhibition of degranulation (±SD) in FD treated and untreated MC.
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degranulation when challenged with 48/80, somatostatin, A23187, and 
poly-L-lysine. Other secretagogues evaluated included C5a, morphine, 
substance P, and LPS which did not produce significant mediator release 
from MC or the pathway was unaffected by FD pretreatment, data not 
shown. These data demonstrate that inhibition of non-IgE-driven MC 
degranulation can be generalized across varies stimuli, as in the case 
of C70-OH and Tetrasulfonate, or selective to a specific stimuli and/or 
signaling pathway, as observed in the case of Biotin and CCC. 
Table 2 represents those FD that were effective at significantly 
inhibiting TNF-α cytokine production from MC. Out of five separate 
MC cultures, no activation of cytokine production was observed with 
compound 48/80 or somatostatin (varying dose and incubation times; 
positive controls using FcεRI antibodies) as others have reported [15].
Calcium ionophore A23187 is a widely used secretagogue which can 
directly increase intracellular calcium concentration (calcium) levels to 
induce mediator release [16]. Nine FD significantly (p< 0.05) inhibited 
degranulation (>10%) (Table 1). Furthermore, 13 FD were capable of 
inhibiting TNF-α cytokine production (>40%) induced by A23187 
(Table 2). Poly-L-lysine is a small polypeptide of the essential amino 
acid L-lysine that can induce MC activation [17,18]. Seven of the FD 
inhibited degranulation (>10%) and six were capable of inhibiting TNF-α 
production (Table 1 and 2). Typical dose response curves of inhibition on 
degranulation and cytokine production are indicated in Figure 1A-D.
Compound 48/80 is a polybasic secretagogue, which has previously 
been shown to activate human MC [19,20] presumably through direct 
interactions with guanosine triphosphate (GTP)-binding proteins and 
MAPK [21]. As seen in Table 1, five FD inhibited degranulation in MC 
challenged with compound 48/80 (>20%). Somatostatin is a peptide 
hormone that has previously been shown to activate human MC [20,22] 
through the G-protein-coupled somatostatin receptor [20,23]. Table 
1 shows a subset of 11 different FD that inhibited degranulation. A 
representative dose response for inhibition is seen in figure 2A and B. 
The effect of FD on non-IgE induced MC PGD2 release
The panel of FD (Tables 1 and 2) evaluated for mediator release were 
investigated to determine if they could reduce PGD2 production in MC. 
TGA, Niacin, Biotin, and Tetrainositol were selected based on to their 
ability to inhibit cytokine production and degranulation in activated 
MC in response to a number of stimuli. Neither Biotin nor Tetrainositol 
resulted in any inhibition of PGD2 production. Mast cells preincubated 
with TGA or Niacin and challenged with A23187, 48/80, or poly-L-
lysine decreased PGD2 production by >60% in all conditions, (Table 
3). No detectable levels of PGD2 where observed in MC-activated with 
somatostatin. Additionally, PGD2 production in IgE challenged (FcεRI) 
MC was reduced nearly 60%. 
The effect of FD on non-IgE induced PBB mediator release
The secretagogues that induce mediator release from PBB are 
Figure 1: Specific FD inhibit human MC calcium-ionophore and poly-L-lysine-induced mediator release in a dose dependent manner. Mast cells were 
incubated overnight with FD, washed and activated with increasing concentrations of A23187 (A and B) or poly-L-lysine (C and D) for 30 minutes (degranulation, A and 
C) or 18 hours (cytokine, B and D). Mediator release was assessed as described in materials and methods. Figures are representative of three separate MC cultures 
with each condition performed in triplicate. 
Fullerene Derivative A23187 + FD* poly-L-lysine + FD*
Biotin 83.9 (±8.0)¥¥¥ no Inh
C70-OH 60.6 (±28.2)¥¥ 16.41 (±10.5)¥
CCC no Inh no Inh
DMAE 41.1  (±12.9)¥ no Inh
Ethanolamine 52.3 (±3.9)¥¥¥ no Inh
Niacin 73.2 (±9.6)¥¥¥ no Inh
NSAID no Inh 12.0 (±6.2)¥
PC4 94.1 (±14.2)¥¥ no Inh
Tetraglutamate 59.7 (±3.0)¥¥¥ 48.3 (±1.86)¥¥¥
Tetrainositol 95.7 (±2.3)¥¥¥ 72.4 (±6.7)¥¥¥
Tetraphosphate 39.3 (±14.3)¥ no Inh
Tetrapyridine 51.7 (±17.5)¥¥ no Inh
Tetrasulfonate 39.9 (±2.5)¥¥¥ no Inh
TGA  93.7 (±4.6)¥¥¥ 70.2 (±1.0)¥¥¥
TTA 98.7 (±3.6)¥¥¥ 66.8 (±3.1)¥¥¥
* FD Treatment at 10 µg/mL. 
¥¥¥ p value < 0.01 / ¥¥ p value < 0.02 / ¥ p value < 0.05 
no Inh = no significant inhibition observed
Table 2: Mean % inhibition of TNF-α (±SD) in FD treated and untreated MC.
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different from those that induce mediator release from MC [24]. The 
effects of FD on N-formyl-methionine-leucine-phenylalanine (fMLP) 
and poly-L-lysine-induced mediator release from PBB are shown in 
table 4. Only Ethanolamine inhibited fMLP-induced degranulation 
(14%). Tetrainositol, TGA, and Niacin inhibited IL-13 release when 
activated with fMLP, but none significantly affected poly-L-lysine 
induced mediator release as seen in table 5. None of the FD evaluated 
inhibited A23187-induced PBB degranulation (data not shown).
The effect of FD on non-IgE mediated induced ROS activity 
and intracellular calcium flux in MC 
We next began to delineate the mechanisms of inhibition focusing 
on MC given the difficulty in obtaining adequate numbers of PBB 
for such studies. The activation of MC and subsequent degranulation 
is calcium-dependent and results in elevated ROS levels [25]. It was 
hypothesized that FD reduced MC degranulation by blocking ROS 
production and calcium responses. Therefore, representative FD was 
selected based on their ability to inhibit A23187, compound 48/80, 
somatostatin, and poly L-lysine-induced degranulation. A23187-
induced increases in ROS and calcium fluctuations were significantly 
reduced by TGA (~50% for ROS, ~70% for calcium) and Ethanolamine 
(~50% for ROS, ~90% for calcium) (Figures 3A and 4A). Niacin and 
Tetrasulfonate significantly reduced compound 48/80-induced ROS 
activity (>30%; Figure 3B), but selectively effected calcium levels 
(Niacin > 80% inhibition and Tetrasulfonate was ineffective; Figure 4B). 
Somatostatin stimulated MC pretreated with Biotin and TTA inhibited 
ROS and calcium activity by approximately 30% (ROS) and 75% 
(calcium) (Figures 3C & 4C). Lastly, figures 3D and 4D demonstrate 
TGA and TTA blunted ROS generation >50% in response to poly-L-
lysine as well as inhibited calcium approximately 30% compared to the 
positive control. Thus, FD appears to inhibit mediator release through 
the blunting of secretagogue-induced cellular increases in ROS and 
intracellular calcium stores.
The effect of FD on non-IgE mediated signaling pathway 
intermediates 
To further delineate the mechanism of action of the FD on non-
IgE-mediated degranulation we examined Western blotting using 
antibodies to the phosphorylation-dependent activated forms of LAT 
and ERK1/ERK2 [26,27]. As seen in figure 5A neither Biotin or TTA 
significantly affected A23187-induced changes in MAPK or LAT. 
Niacin and Tetrasulfatonate both reduced compound 48/80-induced 
phospho-activation of MAPK and LAT (Figure 5B) while Biotin and 
TTA both reduced somatostatin-induced changes (Figure 5C). Both 
TGA and TTA reduced poly-L-lysine induced activation of MAPK with 
minimal effects on LAT. No changes in the phosphorylation state of 
other signaling pathways examined including the Src family of kinases 
and phosphoinositol 3-kinase (PI3K) pathway were observed under 
these conditions (data not shown). 
Discussion 
Mast cells and PBB contribute to several disease processes through 
the release of inflammatory mediators through both IgE and non-IgE 
mechanisms. Thus, therapies aimed at stabilizing them and preventing 
the release of their mediators has been the subject of research for many 
years. For example, omalizumab, the humanized IgE specific IgG1 
monoclonal antibody, which limits the amount of free IgE available to 
bind FcεRI on the surface of MC/PBB, can control severe allergic asthma 
[28,29]. Another MC stabilizer, Cromolyn, has been effectively used 
Activator TGA Niacin Biotin Tetrainositol
A23187 79.8 (±8.4)¥¥¥ no inh no Inh no Inh
48/80 no inh 65.2 (±9.8)¥¥¥ no inh no Inh
somatostatin ND ND ND ND
poly-L-lysine 62.1 (±12.2)¥¥¥ no inh no Inh no Inh
FcERI 59.8  (±7.8)¥¥¥ no inh no inh no Inh
* FD Treatment at 10 µg/mL.
¥¥¥ p value < 0.01 / ¥¥ p value < 0.02 / ¥ p value < 0.05 / no Inh = no significant 
inhibition observed / ND = none detected
Table 3: Mean % inhibition of PGD2 production (±SD) in FD treated and untreated 
MC.
Activator TGA Niacin Biotin Tetrainositol
A23187 79.8 (±8.4)¥¥¥ no inh no Inh no Inh
48/80 no inh 65.2 (±9.8)¥¥¥ no inh no Inh
somatostatin ND ND ND ND
poly-L-lysine 62.1 (±12.2)¥¥¥ no inh no Inh no Inh
FcERI 59.8  (±7.8)¥¥¥ no inh no inh no Inh
* FD Treatment at 10 µg/mL.
¥¥¥ p value < 0.01 / ¥¥ p value < 0.02 / ¥ p value < 0.05 / no Inh = no significant 
inhibition observed / ND = none detected
Table 4: Mean % inhibition of PGD2 production (±SD) in FD treated and untreated 
MC.
Fullerene Derivative FMLP + FD* poly-L-lysine + FD*
Ethanolamine no inh no Inh
Niacin 86.6 (±16.6)¥¥¥ no Inh
Tetrainositol 54.8 (±19.3)¥ no Inh
TGA  83.7 (±19.0)¥¥ no Inh
* FD Treatment at 10 µg/mL.
¥¥¥ p value < 0.01 / ¥¥ p value < 0.02 / ¥ p value < 0.05 
no Inh = no significant inhibition observed
Table 5: Mean % inhibition of IL-13 (±SD) in FD treated and untreated PBB.
Figure 2: Specific FD inhibit human MC compound 48/80- and somatostatin-induced degranulation in a dose dependent manner. Mast cells were incubated 
overnight with FD, washed and activated with increasing concentrations of compound 48/80 (A) or somatostatin (B). Mediator release was assessed as described in 
materials and methods. Figures are representative of three separate MC cultures with each condition performed in triplicate. 
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Figure 3: Specific FD inhibit human MC poly-L-lysine-induced mediator release. Mast cells were incubated overnight with FD, washed 
and activated with optimal concentrations of poly-L-lysine for 30 minutes (A, B) or 4 hours (C, D). Mediator release was assessed as 
described in materials and methods. Figures are representative of three separate MC cultures with each condition performed in triplicate. 
Fullerene derivatives inhibit secretagogue-induced elevations in intracellular ROS levels: Mast cells were incubated overnight with FD, washed and DCF-DA added 
to cells for 30 minutes at 37oC. After washing cells were activated with optimal concentrations of the indicated secretagogue and the fluorescence intensity measured at 
525nm after establishing baseline. Figures show duplicate samples for each condition and are representative of three separate MC cultures. All positive controls (activated 
but not pre-incubated with FD) were represented by red traces and all negative controls (non-activated and non-preincubated with FD) are denoted by black traces.
Figure 4: Fullerene derivatives inhibit secretagogue-induced elevations in intracellular calcium levels. Mast cells were incubated overnight with FD, washed and FURA 
2 added to MC and incubated for 20 minutes at 37oC in the dark. After washing cells were activated with optimal concentrations of the indicated secretagogue and intensity of 
fluorescence was read as a ratio 340 nm and 380 nm wavelengths. Figures show duplicate samples for each condition and are representative of three separate MC cultures. 
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to treat a wide range of MC-driven diseases [30-32]. The significance 
of these studies is that FD has a broad range of inhibitory capabilities 
toward inflammatory cells and has not demonstrated acute toxicity 
in vitro. Since MC/PBB can be induced to secrete their inflammatory 
mediators through several non-overlapping pathways these molecules 
represent a new strategy for therapeutics aimed at those disease 
mediated by these cells such as allergy, asthma, and arthritis. 
As in our previous studies examining IgE-FcεRI-mediated 
degranulation and cytokine production [7,8], the efficacy in of FD was 
strongly dependent upon specific side chains additions; approximately 
20% of the FD tested exhibited significant inhibition. In addition, 
certain secretagogues were unaffected by FD preincubation, indicating 
that the pathway in which the stimuli activates the cell is critical to FD 
efficacy. That is, the FD does not result in a blanket protection of the cells 
response to poster all stimuli, but the FD specifically regulates specific 
signaling pathways. Mast cells and PBB responded differently to fullerene 
preincubation, suggesting that the signal transduction pathways leading 
to mediator release are dissimilar as has been previously reported [33]. 
Further variation in how FD affected cell responses was demonstrated 
in the type of mediator release (degranulation, cytokine, prostaglandin 
production, or a combination thereof). Our strategy, including these 
studies, is to identify those FD that stabilize both IgE and non-IgE 
pathways and pursue more in depth toxicity, pharmacokinetic, and 
biodistribution studies. To this end, TGA is currently a top candidate 
demonstrating no toxicity in vitro and in vivo [9,34], is a potent human 
MC/PBB stabilizer to -FcεRI - dependent stimuli [8], prevents and 
reverses MC-dependent asthma in mouse models [9], and can inhibit 
non--FcεRI responses as demonstrated herein.
There were no clear structure-activity relationships that were 
established from these studies. Particular FD was more effective 
controllers of numerous stimuli, for example Tetrasulfonate showed 
statistically significant reductions in degranulation regardless of 
stimulant used. However, compounds such as CCC were only 
successful at blunting somatostatin-induced degranulation, while it did 
not have any effect on the mediator release elicited by any of the other 
compounds. Mechanistically, these compounds significantly prevented 
activation of MAPK and LAT suggesting they either block the signaling 
intermediates directly or some other intermediate upstream. The 
inhibition of mediator release by FD was paralleled by reductions in 
secretagogue-induced elevations in ROS/calcium levels as well as the 
signaling intermediates MAPK and LAT. These findings are similar to 
those previously demonstrated when examining ROS/calcium levels 
and phosphorylation-of signaling intermediates in FcεRI-challenged 
MC [7,8]. Current studies are aimed at identifying potential intracellular 
binding partners of FD similar to experiments performed to identify 
binding partners in response to FcεRI stimulus [35]. 
Another example in our attempts to rationally designed FD for 
specific disease involves the role of MC in atherosclerosis. A link 
between MC activation and atherosclerosis has now been clearly 
demonstrated [4,36] as their numbers are greatly increased in the 
intima at sites of arterial plaque rupture [36], in advanced plaque lesions 
in the carotid artery [37], and patients who died of acute myocardial 
infarction have an increased number of degranulated MCs at the actual 
site of plaque erosion or rupture [38]. Therapies aimed at treating 
atherosclerosis include Niacin which blocks vascular inflammation, 
ROS, and inflammatory cytokine production in conjunction with 
diminishing NF-ĸB activation [39]. Thus, the Niacin FD was 
constructed and demonstrated to inhibit mediator release from several 
non-IgE pathways through reduced cellular ROS and ERK1/2 phospho-
activation. Mast cell-stabilizing therapies such as Cromolyn have 
shown promise in ApoE models of atherosclerosis (the classic animal 
model for atherosclerosis) where it prevents intra-plaque hemorrhage 
[40]. Thus, strategies aimed at blocking MC activation before it occurs 
could represent a new strategy for treating atherosclerosis.
Prostaglandin D2 is produced by MC and recruits Th2 cells, 
eosinophils, and PBB and it is critical to development of allergic 
diseases such as asthma [24]. In mammalian organs, large amounts of 
PGD2 are found only in the brain and in MC. Previous studies found 
Figure 5: Inhibition of mediator release in compound 48/80, poly-L-lysine, and somatostatin challenged MC involves the down-regulation of MAPK and LAT 
phosphorylation. MC were incubated with or without the FD overnight, washed and activated with the indicated secretagogue. Western blotting was performed as 
described previously in Methods with the indicated Abs and Odyssey IR800-anti-rabbit secondary antibodies. In both cases, the total protein content in lysates was 
measured with the house keeping gene β-Actin and Odyssey IR680-anti-mouse secondary antibody.
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MC-produced PGD2 is the primary mediator of vasodilatation (the 
“niacin flush”) after ingestion of niacin (nicotinic acid) [41]. Previously 
reported data reveals that non-IgE induced PGD2 production was 
attenuated when ROS production was reduced (REF in comment). This 
may be in part due to the mechanism that ROS facilitates the formation 
of a hydrogen bond necessary for PGD synthase activation [42]. In our 
study, the FD evaluated that was effective at reducing ROS generation 
in MC was also effective regulators of PGD2 production, possibly under 
the proposed mechanism of modulating PGD synthase activity.
In conclusion, these studies further delineate the ability of FD to 
affect human MC and PBB responses so that diseases mediated by these 
cell types may be a target for FD-derived therapies. It is demonstrated 
that certain FD can differentially modulate mediator release from MC 
and PBB in response to a variety of secretagogues. This inhibition 
can involve the blunting of activation-induced increases in ROS, the 
release of intracellular stores of calcium, and the phospho-activation 
of MAPK and LAT. Furthermore, the inhibition is strictly governed by 
several factors, the degree and type of functionalization of the fullerene 
nanomaterials, the type of cells that are analyzed, the mediator being 
evaluated, and how the cell is being activated to illicit the mediator 
release. These studies further extend the utility of FD as inhibitors 
of MC mediator release and cytokine production through non-IgE 
mediated pathways. 
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